Singapore Markets closed

SpringWorks Therapeutics, Inc. (SWTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
37.19+1.77 (+5.00%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.78
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 389.75
52-week low 333.33
50-day moving average 350.41
200-day moving average 361.21

Share statistics

Avg vol (3-month) 3496.41k
Avg vol (10-day) 3694.11k
Shares outstanding 549.25M
Implied shares outstanding 6N/A
Float 828.86M
% held by insiders 19.30%
% held by institutions 198.38%
Shares short (28 Apr 2022) 45.81M
Short ratio (28 Apr 2022) 411.92
Short % of float (28 Apr 2022) 420.44%
Short % of shares outstanding (28 Apr 2022) 411.75%
Shares short (prior month 30 Mar 2022) 44.29M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Dec 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-21.08%
Return on equity (ttm)-35.51%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -172.98M
Net income avi to common (ttm)-173.91M
Diluted EPS (ttm)-2.21
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)373.5M
Total cash per share (mrq)7.64
Total debt (mrq)1.29M
Total debt/equity (mrq)0.31
Current ratio (mrq)12.78
Book value per share (mrq)9.59

Cash flow statement

Operating cash flow (ttm)-127.88M
Levered free cash flow (ttm)-63.42M